|
1
|
Zumbrunn J and Trueb B: Primary structure
of a putative serine protease specific for IGF-binding proteins.
FEBS Lett. 398:187–192. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
De Luca A, De Falco M, Severino A,
Campioni M, Santini D, Baldi F, Paggi MG and Baldi A: Distribution
of the serine protease HtrA1 in normal human tissues. J Histochem
Cytochem. 51:1279–1284. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oka C, Tsujimoto R, Kajikawa M,
Koshiba-Takeuchi K, Ina J, Yano M, Tsuchiya A, Ueta Y, Soma A,
Kanda H, et al: HtrA1 serine protease inhibits signaling mediated
by TGF beta family proteins. Development. 131:1041–1053. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grau S, Baldi A, Bussani R, Tian X,
Stefanescu R, Przybylski M, Richards P, Jones SA, Shridhar V,
Clausen T, et al: Implications of the serine protease HtrA1 in
amyloid precursor protein processing. Proc Natl Acad Sci USA.
102:6021–6026. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang Z, Camp NJ, Sun H, Tong Z, Gibbs D,
Cameron DJ, Chen H, Zhao Y, Pearson E, Li X, et al: A variant of
the HTRA1 gene increases susceptibility to age-related macular
degeneration. Science. 314:992–993. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Grau S, Richards PJ, Kerr B, Hughes C,
Caterson B, Williams AS, Junker U, Jones SA, Clausen T and Ehrmann
M: The role of human HtrA1 in arthritic disease. J Biol Chem.
281:6124–6129. 2006. View Article : Google Scholar
|
|
7
|
Marzioni D, Lorenzi T, Altobelli E,
Giannubilo SR, Paolinelli F, Tersigni C, Crescimanno C, Monsurrò V,
Tranquilli AL, Di Simone N, et al: Alterations of maternal plasma
HTRA1 level in preeclampsia complicated by IUGR. Placenta.
33:1036–1038. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baldi A, De Luca A, Morini M, Battista T,
Felsani A, Baldi F, Catricalà C, Amantea A, Noonan DM, Albini A, et
al: The HtrA1 serine protease is down-regulated during human
melanoma progression and represses growth of metastatic melanoma
cells. Oncogene. 21:6684–6688. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Baldi A, Mottolese M, Vincenzi B, Campioni
M, Mellone P, Di Marino M, di Crescenzo VG, Visca P, Menegozzo S,
Spugnini EP, et al: The serine protease HtrA1 is a novel prognostic
factor for human mesothelioma. Pharmacogenomics. 9:1069–1077. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu F, Jin L, Luo TP, Luo GH, Tan Y and
Qin XH: Serine protease HtrA1 expression in human hepatocellular
carcinoma. Hepatobiliary Panceat Dis Int. 9:508–512. 2010.
|
|
11
|
Lehner A, Magdolen V, Schuster T, Kotzsch
M, Kiechle M, Meindl A, Sweep FC, Span PN and Gross E:
Downregulation of serine protease HTRA1 is associated with poor
survival in breast cancer. PLoS One. 8:e603592013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Catalano V, Mellone P, d’Avino A, Shridhar
V, Staccioli MP, Graziano F, Giordani P, Rossi D, Baldelli AM,
Alessandroni P, et al: HtrA1, a potential predictor of response to
cisplatin-based combination chemotherapy in gastric cancer.
Histopathology. 58:669–678. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chien J, Aletti G, Baldi A, Catalano V,
Muretto P, Keeney GL, Kalli KR, Staub J, Ehrmann M, Cliby WA, et
al: Serine protease HtrA1 modulates chemotherapy-induced
cytotoxicity. J Clin Invest. 116:1994–2004. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Moher D, Liberati A, Tetzlaff J and Altman
DG; PRISMA Group: Preferred reporting items for systematic reviews
and meta-analyses: the PRISMA statement. J Clin Epidemiol.
62:1006–1012. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hou Y, Lin H, Zhu L, Liu Z, Hu F, Shi J,
Yang T, Shi X, Guo H, Tan X, et al: The inhibitory effect of IFN-γ
on protease HTRA1 expression in rheumatoid arthritis. J Immunol.
193:130–138. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cipriani V, Leung HT, Plagnol V, Bunce C,
Khan JC, Shahid H, Moore AT, Harding SP, Bishop PN, Hayward C, et
al: Genome-wide association study of age-related macular
degeneration identifies associated variants in the
TNXB-FKBPL-NOTCH4 region of chromosome 6p21.3. Hum Mol Genet.
21:4138–4150. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Morrison MA, Silveira AC, Huynh N, Jun G,
Smith SE, Zacharaki F, Sato H, Loomis S, Andreoli MT, Adams SM, et
al: Systems biology-based analysis implicates a novel role for
vitamin D metabolism in the pathogenesis of age-related macular
degeneration. Hum Genomics. 5:538–568. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu Y, Bhangale TR, Fagerness J, Ripke S,
Thorleifsson G, Tan PL, Souied EH, Richardson AJ, Merriam JE,
Buitendijk GH, et al: Common variants near FRK/COL10A1 and VEGFA
are associated with advanced age-related macular degeneration. Hum
Mol Genet. 20:3699–3709. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Marzioni D, Quaranta A, Lorenzi T, Morroni
M, Crescimanno C, De Nictolis M, Toti P, Muzzonigro G, Baldi A, De
Luca A, et al: Expression pattern alterations of the serine
protease HtrA1 in normal human placental tissues and in gestational
trophoblastic diseases. Histol Histopathol. 24:1213–1222.
2009.PubMed/NCBI
|
|
20
|
Campioni M, Severino A, Manente L, Tuduce
IL, Toldo S, Caraglia M, Crispi S, Ehrmann M, He X, Maguire J, et
al: The serine protease HtrA1 specifically interacts and degrades
the tuberous sclerosis complex 2 protein. Mol Cancer Res.
8:1248–1260. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Spugnini EP, Cardillo I, Fanciulli M,
Crispi S, Vincenzi B, Boccellino M, Quagliuolo L and Baldi A:
Electroporation as a strategy to promote HtrA1 gene uptake and
chemotherapy efficacy in a mouse model of mesothelioma. Front
Biosci (Elite Ed). 5:974–981. 2013.
|
|
22
|
Zurawa-Janicka D, Kobiela J, Stefaniak T,
Wozniak A, Narkiewicz J, Wozniak M, Limon J and Lipinska B: Changes
in expression of serine proteases HtrA1 and HtrA2 during
estrogen-induced oxidative stress and nephrocarcinogenesis in male
Syrian hamster. Acta Biochim Pol. 55:9–19. 2008.PubMed/NCBI
|
|
23
|
Spugnini EP, Cardillo I, Verdina A, Crispi
S, Saviozzi S, Calogero R, Nebbioso A, Altucci L, Cortese G, Galati
R, et al: Piroxicam and cisplatin in a mouse model of peritoneal
mesothelioma. Clinic Cancer Res. 12:6133–6143. 2006. View Article : Google Scholar
|
|
24
|
Sahasrabuddhe NA, Barbhuiya MA, Bhunia S,
Subbannayya T, Gowda H, Advani J, Shrivastav BR, Navani S, Leal P,
Roa JC, et al: Identification of prosaposin and transgelin as
potential biomarkers for gallbladder cancer using quantitative
proteomics. Biochem Biophys Res Commun. 446:863–869. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tatenhorst L, Senner V, Püttmann S and
Paulus W: Regulators of G-protein signaling 3 and 4 (RGS3, RGS4)
are associated with glioma cell motility. J Neuropathol Exp Neurol.
63:210–222. 2004.PubMed/NCBI
|
|
26
|
Wang N, Eckert KA, Zomorrodi AR, Xin P,
Pan W, Shearer DA, Weisz J, Maranus CD and Clawson GA:
Down-regulation of HtrA1 activates the epithelial-mesenchymal
transition and ATM DNA damage response pathways. PLoS One.
7:e394462012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
He X, Ota T, Liu P, Su C, Chien J and
Shridhar V: Downregulation of HtrA1 promotes resistance to anoikis
and peritoneal dissemination of ovarian cancer cells. Cancer Res.
70:3109–3118. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Clawson GA, Bui V, Xin P, Wang N and Pan
W: Intracellular localization of the tumor suppressor HtrA1/Prss11
and its association with HPV16 E6 and E7 proteins. J Cell Biochem.
105:81–88. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chien J, Staub J, Hu SI, Erickson-Johnson
MR, Couch FJ, Smith DI, Crowl RM, Kaufmann SH and Shridhar V: A
candidate tumor suppressor HtrA1 is downregulated in ovarian
cancer. Oncogene. 23:1636–1644. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Baldi A, Battista T, De Luca A, Santini D,
Rossiello L, Baldi F, Natali PG, Lombardi D, Picardo M, Felsani A,
et al: Identification of genes down-regulated during melanoma
progression: a cDNA array study. Exp Dermatol. 12:213–218. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tiaden AN and Richards PJ: The emerging
roles of HTRA1 in musculoskeletal disease. Am J Pathol.
182:1482–1488. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Skorko-Glonek J, Zurawa-Janicka D, Koper
T, Jarzab M, Figaj D, Glaza P and Lipinska B: HtrA protease family
as therapeutic targets. Curr Pharm Des. 19:977–1009. 2013.
View Article : Google Scholar
|
|
33
|
Singh N, Kuppili RR and Bose K: The
structural basis of mode of activation and functional diversity: a
case study with HtrA family of serine proteases. Arch Biochem
Biophys. 516:85–96. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zurawa-Janicka D, Skorko-Glonek J and
Lipinska B: HtrA proteins as targets in therapy of cancer and other
diseases. Expert Opin Ther Targets. 14:665–679. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
MacDonald TJ, Pollack IF, Okada H,
Bhattacharya S and Lyons-Weiler J: Progression-associated genes in
astrocytoma identified by novel microarray gene expression data
reanalysis. Methods Mol Biol. 377:203–222. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chien J, Campioni M, Shridhar V and Baldi
A: HtrA serine proteases as potential therapeutic targets in
cancer. Curr Cancer Drug Targets. 9:451–468. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xu Y, Jiang Z, Zhang Z, Sun N, Zhang M,
Xie J, Li T, Hou Y and Wu D: HtrA1 downregulation induces cisplatin
resistance in lung adenocarcinoma by promoting cancer stem
cell-like properties. J Cell Biochem. 115:1112–1121. 2014.
View Article : Google Scholar
|
|
38
|
Neuhausen SL, Brummel S, Ding YC, et al:
Genetic variation in IGF2 and HTRA1 and breast cancer risk among
BRCA1 and BRCA2 carriers. Cancer Epidemiol Biomarkers Prev.
20:1690–1702. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
He X, Khurana A, Maguire JL, Chien J and
Shridhar: HtrA1 sensitizes ovarian cancer cells to
cisplatin-induced cytotoxicity by targeting XIAP for degradation.
Int J Cancer. 130:1029–1035. 2012. View Article : Google Scholar
|
|
40
|
Folgueira MA, Carraro DM, Brentani H,
Patrão DF, Barbosa EM, Netto MM, Caldeira JR, Katayama ML, Soares
FA, Oliveira CT, et al: Gene expression profile associated with
response to doxorubicin-based therapy in breast cancer. Clin Cancer
Res. 11:7434–7443. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Barros Filho MC, Katayama ML, Brentani H,
Abreu AP, Barbosa EM, Oliveira CT, Góes JC, Brentani MM and
Folgueira MA: Gene trio signatures as molecular markers to predict
response to doxorubicin cyclophosphamide neoadjuvant chemotherapy
in breast cancer patients. Braz J Med Biol Res. 43:1225–1231. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
D’Angelo V, Pecoraro G, Indolfi P,
Iannotta A, Donofrio V, Errico ME, Indolfi C, Ramaglia M, Lombardi
A, Di Martino M, et al: Expression and localization of serine
protease Htra1 in neuroblastoma: correlation with cellular
differentiation grade. J Neurooncol. 117:287–294. 2014. View Article : Google Scholar
|
|
43
|
Lorenzi T, Lorenzi M, Altobelli E,
Marzioni D, Mensà E, Quaranta A, Paolinelli F, Morroni M,
Mazzucchelli R, De Luca A, et al: HtrA1 in human urothelial bladder
cancer: a secreted protein and a potential novel biomarker. Int J
Cancer. 133:2650–2661. 2013.PubMed/NCBI
|
|
44
|
Yu Y, Shao W, Hu Y, Zhang J, Song H and
Zhu ZH: HtrA1 expression associated with the occurrence and
development of esophageal cancer. World J Surg Oncol. 10:1792012.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xia J, Wang F, Wang L and Fan Q: Elevated
serine protease HtrA1 inhibits cell proliferation, reduces
invasion, and induces apoptosis in esophageal squamous cell
carcinoma by blocking the nuclear factor-κB signaling pathway.
Tumor Biol. 34:317–328. 2013. View Article : Google Scholar
|
|
46
|
Mullany SA, Moslemi-Kebria M, Rattan R,
Khurana A, Clayton A, Ota T, Mariani A, Podratz KC, Chien J and
Shridhar V: Expression and functional significance of HtrA1 loss in
endometrial cancer. Clin Cancer Res. 17:427–436. 2011. View Article : Google Scholar :
|
|
47
|
Narkiewicz J, Lapinska-Szumczyk S,
Zurawa-Janicka D, Skorko-Glonek J, Emerich J and Lipinska B:
Expression of human HtrA1, HtrA2, HtrA3 and TGF-beta1 genes in
primary endometrial cancer. Oncol Rep. 21:1529–1537.
2009.PubMed/NCBI
|
|
48
|
Bowden MA, Di Nezza-Cossens LA, Jobling T,
Salamonsen LA and Nie G: Serine proteases HTRA1 and HTRA3 are
down-regulated with increasing grades of human endometrial cancer.
Gynecol Oncol. 103:253–260. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zurawa-Janicka D, Kobiela J, Galczynska N,
Stefaniak T, Lipinska B, Lachinski A, Skorko-Glonek J, Narkiewicz
J, Proczko-Markuszewska M and Sledzinski Z: Changes in expression
of human serine protease HtrA1, HtrA2 and HtrA3 genes in benign and
malignant thyroid tumors. Oncol Rep. 28:1838–1844. 2012.PubMed/NCBI
|
|
50
|
Narkiewicz J, Klasa-Mazurkiewicz D,
Zurawa-Janicka D, Skorko-Glonek J, Emerich J and Lipinska B:
Changes in mRNA and protein levels of human HtrA1, HtrA2 and HtrA3
in ovarian cancer. Clin Biochem. 41:561–569. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Esposito V, Campioni M, De Luca A,
Spugnini EP, Baldi F, Cassandro R, Mancini A, Vincenzi B, Groeger
A, Caputi M, et al: Analysis of HtrA1 serine protease expression in
human lung cancer. Anticancer Res. 26:3455–3459. 2006.PubMed/NCBI
|
|
52
|
Horie-Inoue K and Inoue S: Genomic aspects
of age-related macular degeneration. Biochem Biophysis Res Commun.
452:263–275. 2014. View Article : Google Scholar
|
|
53
|
Altobelli E, Lattanzi A, Paduano R,
Varassi G and di Orio F: Colorectal cancer prevention in Europe:
burden of disease and status of screening programs. Prev Med.
62:132–141. 2014. View Article : Google Scholar : PubMed/NCBI
|
